Latest revenue
$202.0M
as of 2026-03-31
Latest net income
$1.65B
as of 2026-03-31
Net margin
818.8%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $75.72B
- Enterprise value
- $99.58B
- P/E (trailing)
- 11.4×
- Forward P/E
- —
- P/B
- 1.79×
- Dividend yield
- 2.1%
- 52-wk high
- $338.89
- 52-wk low
- $239.51
- Beta
- —
- Shares out
- 264.5M
5-year trend
What this company does
Cigna runs a pharmacy benefit manager (Evernorth) that processes drug claims, manages formularies, and dispenses specialty and home-delivery prescriptions, alongside a smaller commercial and international health insurance arm (Cigna Healthcare). Pharmacy revenues dominate the business at $54 billion of $68 billion in quarterly revenue, dwarfing insurance premiums. Cigna has pivoted away from Medicare Advantage, completing the sale of that business to HCSC in March 2025, refocusing the company on pharmacy services and employer-sponsored health plans.
Generated from CI's filing dated 2026-04-30
Key risks
- Premium revenues fell 23% YoY ($12.7B→$9.8B) following the March 2025 divestiture of Medicare Advantage to HCSC, shrinking insurance scale.
- Pharmacy is now ~79% of revenue ($54B) but ran at near-zero gross margin (costs $54.1B), leaving Evernorth highly exposed to PBM pricing/regulatory pressure.
- Goodwill and intangibles total $72.9B vs. $42.2B equity; any Evernorth/Cigna Healthcare impairment would materially impair book value.
Generated from CI's filing dated 2026-04-30
Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $202.0M | -15.1% | $1.65B | +25.0% | 818.8% |
Q3 2025 2025-09-30 | $233.0M | +174.1% | — | — | — |
Q2 2025 2025-06-30 | $236.0M | -26.5% | — | — | — |
Q1 2025 2025-03-31 | $238.0M | -17.9% | $1.32B | — | 555.9% |
Q3 2024 2024-09-30 | $85.0M | -73.5% | — | — | — |
Q2 2024 2024-06-30 | $321.0M | +15.5% | — | — | — |
Q1 2024 2024-03-31 | $290.0M | — | — | — | — |
Q3 2023 2023-09-30 | $321.0M | — | — | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Hospital & Medical Service Plans · SIC 6324
Your notes
Keep private notes on CI — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$999.9K
Insider selling
$70.4M
Net activity
−$69.4M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CI
Institutional value
$19.25B
Total shares held
75.3M
Distinct holders
736
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 17.1M | $4.57B | — | New |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6.2M | $1.64B | — | New |
| 3 | GQG Partners LLC | 6.0M | $1.60B | — | New |
| 4 | Invesco Ltd. | 2.5M | $665.1M | — | New |
| 5 | DIMENSIONAL FUND ADVISORS LP | 2.4M | $647.0M | — | New |
| 6 | Davis Selected Advisers | 2.2M | $595.9M | — | New |
| 7 | Legal & General Group Plc | 2.1M | $554.1M | — | New |
| 8 | Nuveen, LLC | 1.8M | $492.7M | — | New |
| 9 | Boston Partners | 1.8M | $474.2M | — | New |
| 10 | Bank of New York Mellon Corp | 1.7M | $450.4M | — | New |
| 11 | VANGUARD FIDUCIARY TRUST CO | 1.5M | $396.3M | — | New |
| 12 | DEUTSCHE BANK AG\ | 1.3M | $348.8M | — | New |
| 13 | UBS Group AG | 907.8K | $242.2M | — | New |
| 14 | Russell Investments Group, Ltd. | 824.5K | $219.3M | — | New |
| 15 | National Pension Service | 785.5K | $209.5M | — | New |
| 16 | Swiss National Bank | 783.9K | $209.1M | — | New |
| 17 | Sumitomo Mitsui Trust Group, Inc. | 759.5K | $202.6M | — | New |
| 18 | LYRICAL ASSET MANAGEMENT LP | 750.1K | $200.1M | — | New |
| 19 | HSBC HOLDINGS PLC | 665.3K | $177.1M | — | New |
| 20 | Swedbank AB | 663.0K | $176.9M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
Premiums collapsed from $12.7B to $9.8B year-over-year—how much reflects the HCSC divestiture versus underlying membership losses, and what's the run-rate margin impact?
- 2
Pharmacy and other service costs payable fell $4.6B this quarter, draining operating cash flow to $1.1B from $1.9B—is this a working capital reset or rebate timing normalizing?
- 3
With zero buybacks this quarter versus $1.5B in Q1 2025 and short-term debt up to $1.5B, are you signaling capital constraints or pending M&A?
Refreshed when CI files a new report · last from 2026-04-30